Mark Hope

Mark Hope is a dynamic global pharma and asset leader, with expertise in drug development and regulatory affairs and a notable focus in various therapeutic areas including Neurology, Immunology, CV-Metabolism, and Oncology.

He is well-respected for his leadership skills, EQ-IQ balance, and ability to deliver patient and organizational value through innovative drug development strategies.

Mark maximizes patient outcomes by focusing on innovation and ecosystem evolution, showcasing strategic agility and an entrepreneurial spirit.

He is known for encouraging talent growth and achieving high employee engagement scores, with a natural curiosity for new trends and technologies.

Mark has a strong educational background, including a Stanford Executive MBA from the SEP program, a Diploma in Regulatory Affairs from TOPRA/University of Cardiff, and a BSc. Hons in Chemistry from the University of Nottingham.

Throughout his career, Mark has held key positions such as Head of Neurodegeneration Mission and Global Head of Regulatory Affairs at UCB, Global Head of CNS And Metabolic Regulatory Affairs at Roche, and various leadership roles at Hoffmann-La Roche.

His career highlights include leading the development of late phase assets, brand management, and corporate cross-functional strategies in Neurodegeneration and Gene Therapy.

Mark's hands-on experience spans across the US and EU regions, working with global health authorities and leading regulatory and drug development initiatives.

His expertise includes regulatory filings, FDA/EMA advisory committees, and team development, displaying a strong focus on organizational design and business acumen.